Skip to main content
NCBI home page
American Journal of Men's Health logoLink to American Journal of Men's Health
. 2025 Oct 14;19(5):15579883251377737. doi: 10.1177/15579883251377737

The Efficacy and Safety of Daily Use of Tadalafil in Treatment of Premature Ejaculation: A Systematic Review and Meta-Analysis

Shikai Zhao 1,*, Jiankun Zhang 2,3,*, Yuanshan Cui 3, Yunbo Ma 4, Huilei Yan 4,✉
PMCID: PMC12536122

Abstract

The purpose of this meta-analysis was to evaluate the efficacy and safety of the once-daily use of 5 mg tadalafil in the treatment of patients with premature ejaculation. The databases MEDLINE/PubMed, EMBASE, and Cochrane Library from January 1980 until December 2024 were searched to identify randomized controlled trials (RCTs) that referred to the use of tadalafil for the treatment of premature ejaculation. A systematic review and meta-analysis was conducted. Five publications involving 397 patients were included in the meta-analysis. No statistically significant difference was identified between tadalafil and placebo for intravaginal ejaculatory latency time (IELT; mean difference [MD] = 68.43; 95% confidence interval [CI] = [−12.59 to 149.45]; p = .10) and Arabic index of premature ejaculation (AIPE; MD = 11.44; 95% CI = [−11.79, 34.66]; p = .33). Tadalafil appeared to improve the score of the premature ejaculation diagnostic tool (PEDT; MD = −0.30; 95% CI = [−0.57, −0.03]; p = .03). In terms of adverse events, the tadalafil group was significantly higher than the placebo group for headache (odds ratio [OR] = 16.06, 95% CI = [3.80, 67.94], p = .0002), back pain and myalgia (OR = 21.76, 95% CI = [4.17, 113.53], p = .0003), flushing (OR = 6.05, 95% CI = [1.05, 34.92], p = .04), and dyspepsia (OR = 10.27, 95% CI = [1.90, 55.96], p < .007). Our meta-analysis indicates that the once-daily use of 5 mg tadalafil had no statistically significant effect in the treatment of premature ejaculation. Meanwhile, the tadalafil therapy showed a higher risk of complications.

Keywords: tadalafil, premature ejaculation, meta-analysis, randomized controlled trials

Introduction

The premature ejaculation (PE) is described as the phenomenon that occurs when ejaculation happens persistently sooner than a man or his partner would like during sexual intercourse (Raveendran & Agarwal, 2021). The prevalence ranges from 20% to 30% in sexually active age men (Laumann et al., 2005; Patrick et al., 2005). The International Society for Sexual Medicine (ISSM) defines PE as: (a) ejaculation which always or nearly always occurs prior to or within about 1 minute of vaginal penetration (lifelong PE), or, a clinically significant and bothersome reduction in latency time, often to about 3 minutes or less (acquired PE); (b) inability to delay ejaculation on all or nearly all vaginal penetrations; and (c) negative personal consequences, such as distress, bother, frustration, and/or the avoidance of sexual intimacy (Serefoglu et al., 2014).

Although the exact etiology of PE remains unclear, the leading theories focus on the disturbances in the activities of neurotransmitters, penile hypersensitivity, erectile dysfunction (ED), genetic predisposition, hormonal problems, and prostatic diseases (Culha et al., 2020; Gopalakrishna et al., 2021; McMahon et al., 2016). The treatment of PE includes non-pharmacological and pharmacological treatment. Psychological therapy and various behavioral therapies are also used in the treatment of PE (Raveendran & Agarwal, 2021). Pharmaceutical approaches predominantly comprise the prescription of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, phosphodiesterase type 5 inhibitors (PDE5-Is), and/or topical anesthetics (Leisegang et al., 2023).

Tadalafil, available in both once-daily and on-demand dosing regimens, is a PDE5-I that has been globally approved for the treatment of ED (Wang et al., 2023). In recent years, clinical trials have explored the once-daily administration of tadalafil for the treatment of PE. Some of these trials have yielded encouraging outcomes, suggesting that daily use of tadalafil may significantly improve PE; however, others have found no significant difference compared to a placebo. Until now, there has been no systematic meta-analysis assessing the efficacy and safety of a once-daily 5 mg dose of tadalafil in the treatment of PE. Consequently, we conducted a comprehensive meta-analysis to evaluate the effects of once-daily use of tadalafil in patients suffering from PE.

Method

Inclusion and Exclusion Criteria

We included randomized controlled trials (RCTs) in which people with lifelong PE according to the ISSM married and in a stable sexual relationship for at least 1 to 6 months. We included studies provided that preliminary results were available. We also included non-English studies in the meta-analysis. RCTs were required to meet the following inclusion criteria: (a) studied the efficacy and safety of once-daily use of tadalafil for the treatment of PE, (b) provided sufficient data for analysis, including primary outcome intravaginal ejaculatory latency time (IELT) and adverse events, and (c) the full text of the study could be accessed. The exclusion criteria were as follows: (a) publications that did not contain original data; (b) duplicated publications; (c) no use of IELT; and (d) studies without merging analysis data.

Search Strategy and Trial Selection

Trials were identified through searches of MEDLINE/PubMed, Embase, and Cochrane Library, as well as gray literature and reference lists of systematic reviews through December, 2024. The following search terms were used: Tadalafil, Premature ejaculation, Phosphodiesterase 5 Inhibitors, and Randomized controlled trials. Abbreviations (PE, PDE5, RCT) were also searched. Two independent researchers screened and assessed for eligibility of relevant RCTs according to the inclusion and exclusion criteria. Researchers resolve disagreements through discussion. The study selection process is presented by a diagram in Figure 1.

Figure 1.

The diagram shows a flowchart of study selection for a research paper, detailing the process of identifying and excluding articles from databases MEDLINE, EMBASE, and the Cochrane Controlled Trials Register.

Open in a new tab

Flow Diagram of the Study Selection Process

The researchers independently performed the data extraction for the meta-analysis, which included the following: (a) the name of the first author and the publication year, (b) the design of the study, (c) the treatment therapy that the patients received, (d) the sample size, (e) the duration of treatment, (f) the outcome measurements, and (g) the eligibility criteria of the study. The characteristics of the individual studies are listed in Table 1.

Table 1.

Characteristics of Individual Study.

Study Design Experimental group Control group Sample size Treatment period Outcome measurements Inclusion criteria
Experimental Control
Abou Faddan et al. (2022) RCT Tadalafil 5 mg once daily Placebo once daily 27 28 3 months IELT, PEDT Patients 20–35 years with lifelong PE according to the ISSM married and in a stable sexual relationship for at least 1 month
Abu El-Hamd (2018) RCT Tadalafil 5 mg once daily Multivitamin tablet once daily 50 50 6 weeks IELT, AIPE Patients ≥20 years with lifelong PE according to the ISSM married and in a stable sexual relationship for at least 1 month
Al-Shukri et al. (2022) RCT Tadalafil 5 mg once daily Placebo once daily 20 10 1 moth IELT, PEDT, AIPE Patients 18–25 years with lifelong PE according to the ISSM in stable heterosexual, monogamous relationships for at least 6 months
Dell’Atti et al. (2017) RCT Tadalafil 5 mg once daily Lidocaine spray 10 g/100 ml before intercourse 27 25 3 months IELT Patients with lifelong PE according to the ISSM in stable heterosexual, monogamous relationships for at least 3 months
Mohamed Gharib et al. (2022) RCT Tadalafil 5 mg once daily Placebo once daily 80 80 3 moths IELT Patients 18–65 years who had ED and lifelong PE for the last 6 months of a continuous marriage relationship
Open in a new tab

Note. RCT = Randomized Controlled Trials IELT = Intravaginal Ejaculatory Latency Time; PEDT = Premature Ejaculation Diagnostic Tool; PE = Premature Ejaculation; AIPE = Arabic Index of Premature Ejaculation; ED = Erectile Dysfunction.

Quality Assessment

The quality of the RCTs was assessed in terms of sequence generation, the concealment of allocation procedures, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. The studies were then classified qualitatively according to the guidelines published in the Cochrane Handbook for Systematic Reviews of Interventions v.5.1.0 (Higgins et al., 2011). Based on the quality assessment criteria, each study was rated and assigned to one of the three following quality categories: +, low risk of bias; ?, unclear risk of bias; -, high risk of bias. Differences were resolved by discussion among the authors. The bias of all the identified studies that we searched was at low risk in general (Table 2).

Table 2.

ROB for Included Randomized Controlled Trials.

Study Sequence generation Allocation concealment Blinding Incomplete outcome data Selective outcome reporting Other sources of bias
Abou Faddan et al. (2022) + ? + + + +
Abu El-Hamd (2018) + ? + + + +
Al-Shukri et al. (2022) ? ? ? + + +
Dell’Atti et al. (2017) + ? ? ? + +
Mohamed Gharib et al. (2022) + + ? + + +
Open in a new tab

Note. ROB: Risk Of Bias; +, Indicates Low Risk of Bias; ?, Unclear Risk of Bias; -, High Risk of Bias.

Outcome Measurement and Statistical Analysis

Our primary outcome, IELT, was defined as the time from intravaginal intromission until intravaginal ejaculation. The IELT was calculated by female partners using a stopwatch. The secondary outcome was the Arabic Index of Premature Ejaculation (AIPE) and Premature Ejaculation Diagnostic Tool (PEDT). The most commonly reported adverse events are used to assess safety. Regarding the dichotomous outcomes, odds ratio (OR) with a 95% confidence interval (CI) was used where available. Mean difference (MD) with 95% CI was used to report continuous outcomes. The comparative effects were initially analyzed by the traditional pairwise meta-analysis method using Cochrane Collaboration review manager software (RevMan v.5.3.0). We estimated the odd risk for dichotomous outcomes and the MD for continuous outcomes pooled across studies by using the DerSimonian & Laird random-effects model (DerSimonian & Laird, 1986). A “fixed-effects” statistical model was used if there was no conspicuous heterogeneity. A “random-effects” model was used if heterogeneity was detected. The tests for heterogeneity were performed using Chi-square tests with the significance level set at I2 ≥ 50%. A sensitivity analysis was performed to determine whether the heterogeneity was a result of low study quality.

Results

We identified six eligible RCTs (Abou Faddan et al., 2022; Abu El-Hamd, 2018; Al-Shukri et al., 2022; Dell’Atti et al., 2017; Mohamed Gharib et al., 2022; Ozcan et al., 2017); one was excluded for lacking comparison group. Finally, five RCTs involving 397 lifelong PE male patients in a stable sexual relationship were included in our meta-analysis. In these studies, patients were randomized to the treatment group receiving 5 mg tadalafil once daily. The comparison group of four studies was placebo, and one study used the lidocaine spray.

IELT

A total of five studies including 397 patients (204 in the tadalafil group and 193 in the control group) contributed to the analysis of the change of IELT. Heterogeneity was found among the trials (p < .00001, I2 = 100%), and a random-effects model was thus chosen for the analysis. The forest plots reflected an MD of 68.43 (95% CI = [−12.59, 149.45], p = .10). The results revealed that there was no marked difference between the once-daily use of 5 mg tadalafil and placebo in the change of IELT for patients with lifelong PE (Figure 2).

Figure 2.

A graphical representation comparing the effect of Tadalafil versus placebo on the Intravaginal Ejaculatory Latency Time (IELT), incorporating statistical measures and a forest plot highlighting the mean differences and confidence intervals.

Open in a new tab

Forest Plot Shows Changes in Intravaginal Ejaculatory Latency Time (IELT; Min)

Note. SD = Standard Deviation; IV = Inverse Variance; CI = Confidence Interval.

AIPE and PEDT

Only two studies reported the AIPE and PEDT. When these studies were pooled, the analysis demonstrated that there was no statistically significant variance in the change of AIPE score between the treatment and placebo arms. The MD for AIPE scores was 11.4 (95% CI = [−11.79, 34.66], p = .33), indicating that daily administration of 5 mg tadalafil did not substantially enhance AIPE scores in comparison to placebo. For the change of PEDT scores, the forest plots reflected an MD of −0.30 (95% CI = [−0.57, −0.03], p = .03). The results revealed that once-daily use of 5 mg tadalafil statistically improved the PEDT scores. However, the studies only encompassed a total of 85 patients. This is illustrated in Figures 3 and 4.

Figure 3.

Tabulated forest plot shows changes in score of Arabic Index of Premature Ejaculation (API E), with standard deviations and inverse variances for tadarof vs placebo groups.

Open in a new tab

Forest Plot Shows Changes in Score of Arabic Index of Premature Ejaculation (AIPE)

Note. SD = Standard Deviation; IV = Inverse Variance; CI = Confidence Interval.

Figure 4.

In Figure 11, a forest plot illustrates the 95% confidence intervals for standard deviations and mean differences comparing PEDT scores between Tadalafil and Placebo, with Tadalafil showing a significant mean difference.

Open in a new tab

Forest Plot Shows Changes in Score of Premature Ejaculation Diagnostic Tool (PEDT)

Note. SD = Standard Deviation; IV = Inverse Variance; CI = Confidence Interval.

Adverse Events

All the RCTs which included in the meta-analysis did not report serious adverse effects. The most common adverse events in patients treated with tadalafil included headache, myalgia, back pain, flushing, and dyspepsia. Four studies with available data were included in our analysis. From the analysis, the once-daily use of 5 mg tadalafil was associated with a significantly higher incidence of adverse events (headache [OR = 16.06, 95% CI = [3.80, 67.94], p = .0002], back pain and myalgia [OR = 21.76, 95% CI = [4.17, 113.53], p = .0003], flushing [OR = 6.05, 95% CI = [1.05, 34.92], p = .04], and dyspepsia [OR = 10.27, 95% CI = [1.90, 55.96], p < .007]; Figure 5).

Figure 5.

This forest plot presentation compares the risks of adverse events caused by tadalafil versus placebo across four study subsets: Abu 2022, Abu 2018, L DellAtti 2017, and Mohamed 2022.

Open in a new tab

Forest Plot Shows Differences Between the Groups for Adverse Events

Note. M-H = Mantel–Haenszel test; CI = confidence interval.

Discussion

Due to its highly complex etiology and pathophysiology, PE has seen numerous treatment options proposed and implemented to date. The treatment of PE primarily relies on medications, the majority of which are used off-label, with the exception of dapoxetine, while local anesthetic agents and SSRIs have repeatedly demonstrated their effectiveness in the management of lifelong PE (Asimakopoulos et al., 2012). PDE5-Is are being studied in numerous clinical trials for the potential benefits they offer in the treatment of PE. PDE5-Is increase the activity of cyclic guanosine monophosphate (cGMP) and nitric oxide (NO) in the medial preoptic area. Thus, this leads to a reduction in sympathetic nervous system tone and may ultimately result in delayed ejaculation (Krishnappa et al., 2019; Pfaus, 1999). It is thought that PDE5-Is can delay ejaculation by relaxing smooth muscles in peripheral organs such as the vas deferens, seminal vesicles, prostate, and urethra via the same NO-cGMP pathway (Chen et al., 2007). Besides, PDE5-Is could increase the perception of ejaculatory control, ejaculatory confidence, and overall sexual satisfaction (Raveendran & Agarwal, 2021).

In 2008, Mattos et al. first reported that tadalafil 20 mg on demand significantly improved the IELT compared with placebo (p = .001; Mattos et al., 2008). Previous meta-analyses shown an overall positive effect of the treatment of PE through the use of PDE5-Is (Asimakopoulos et al., 2012; Sun et al., 2015; Zhang et al., 2020). There were very few RCTs involving tadalafil in the previous meta-analyses, and they were all about on-demand use of tadalafil. In 2017, Ozcan et al. first evaluated the effect of 5-mg tadalafil daily use on PE in a single-blind RCT; they found mean IELT values in the PE group showed statistically significant improvement from baseline values (from 40.8 ± 8.1 to 190 ± 19.8 s, p < .05; Ozcan et al., 2017). To our knowledge, this is the first meta-analysis conducted to assess the efficacy and adverse events of once-daily use of 5 mg tadalafil in the treatment of PE.

The studies included in our analysis are all high-quality RCTs involving male patients from various regions, including Russia, Egypt, and Italy, with the aim of exploring the potential of tadalafil in the treatment of lifelong PE. All studies administered a 0.5-mg dose of tadalafil, which is consistent with the commonly used clinical dose. Among the studies, three did not specify whether blinding was employed, while two explicitly mentioned the use of a single-blind design. One study compared tadalafil with the local anesthetic lidocaine, while the others used a placebo, which did not show a significant improvement in ejaculation time, serving as the control. In terms of participant demographics, two studies included young male participants, while the remaining three focused on adult males. Future research could explore the differences in the effects of tadalafil across different age groups by conducting subgroup analyses based on age.

Regarding the results, four studies concluded that tadalafil was effective in prolonging ejaculation time, whereas one study found no significant effect. This finding contradicts the results of our analysis, where we primarily compared the change in IELT between tadalafil and placebo groups relative to baseline values. Our results indicate that tadalafil 5 mg once daily does not have a statistically significant effect on increasing IELT and AIPE, and the incidence of adverse events is higher. The discrepancy may be attributed to several factors, including sample size. Specifically, studies with larger sample sizes tend to produce more reliable results. In order to assess the impact of individual studies on the overall results, a sensitivity analysis was performed by sequentially excluding each study and re-conducting the meta-analysis. The findings indicated that the overall effect remained consistent, with no significant changes observed after the exclusion of any single study. This suggests that the conclusions drawn from this meta-analysis are robust and not unduly influenced by any individual study. Due to the results, the once-daily use of 5 mg tadalafil is not a promising alternative to de novo therapeutic strategies in the treatment of PE.

A number of limitations of the current study were identified. First, only five RCTs with small sample sizes were included in the meta-analysis. Second, in all RCTs included in the meta-analysis, the baseline characteristics of the patients are not completely consistent. Third, the specific components of the placebo in the control group were not clearly stated in some experiments; only two studies pointed out that multivitamin or lidocaine spray as placebo. Fourth, the treatment period and follow-up time of all RCTs ranged from 1 to 3 months. In addition, the findings of this meta-analysis were derived after manipulation of the data, which may also have resulted in bias. Further high-quality RCTs are strongly encouraged to learn more about once-daily use of 5 mg tadalafil in the treatment of PE.

Conclusions

In conclusion, our meta-analysis indicates that the once-daily use of 5 mg tadalafil had no statistically significant effect in the treatment of PE. Meanwhile, the tadalafil therapy showed a higher risk of adverse events.

Footnotes

Funding: The authors received no financial support for the research, authorship, and/or publication of this article.

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. Abou Faddan A. H., Gaber H. D., Oamonov D. (2022). Effect of a tadalafil 5-mg single daily dose on lifelong premature ejaculation: A single-blinded placebo-controlled study. Arab Journal of Urology, 20(2), 100–104. 10.1080/2090598x.2021.2007464 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abu El-Hamd M. (2018). Efficacy and safety of daily use of tadalafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial. Andrologia, 50(5), e13005. 10.1111/and.13005 [DOI] [PubMed] [Google Scholar]
  3. Al-Shukri A. S., Kostyukov S. V., Maksimova A. V., Pygamov K. G., Dubinsky V. Y. (2022). Tadalafil-SZ in the treatment of premature ejaculation in young age men: A comparative placebo-controlled study. Urology Reports (St.-Petersburg), 12(2), 147–155. [Google Scholar]
  4. Asimakopoulos A. D., Miano R., Finazzi Agrò E., Vespasiani G., Spera E. (2012). Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? a systematic review and meta-analysis. Journal of Sexual Medicine, 9(9), 2404–2416. 10.1111/j.1743-6109.2011.02628.x [DOI] [PubMed] [Google Scholar]
  5. Chen J., Keren-Paz G., Bar-Yosef Y., Matzkin H. (2007). The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: A critical analysis of basic science and clinical data. European Urology, 52(5), 1331–1339. 10.1016/j.eururo.2007.08.005 [DOI] [PubMed] [Google Scholar]
  6. Culha M. G., Tuken M., Gonultas S., Cakir O. O., Serefoglu E. C. (2020). Frequency of etiological factors among patients with acquired premature ejaculation: Prospective, observational, single-center study. International Journal of Impotence Research, 32(3), 352–357. 10.1038/s41443-019-0188-x [DOI] [PubMed] [Google Scholar]
  7. Dell’Atti L., Galosi A. B., Ippolito C. (2017). A randomized single-center study to compare the efficacy and tolerability of tadalafil once daily plus lidocaine anesthetic spray on premature ejaculation. European Review for Medical and Pharmacological Sciences, 21(5), 1036–1040. [PubMed] [Google Scholar]
  8. DerSimonian R., Laird N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188. 10.1016/0197-2456(86)90046-2 [DOI] [PubMed] [Google Scholar]
  9. Gopalakrishna A., Bole R., Alom M., Meng Y., Jimbo M., Trost L., Helo S., Kohler T., Ziegelmann M. (2021). Characteristics of men who are bothered by rapid ejaculation: Results from clinical intake surveys. International Journal of Impotence Research, 33(3), 369–375. 10.1038/s41443-020-0277-x [DOI] [PubMed] [Google Scholar]
  10. Higgins J. P., Altman D. G., Gøtzsche P. C., Jüni P., Moher D., Oxman A. D., Savovic J., Schulz K. F., Weeks L., Sterne J. A. (2011). The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. British Medical Journal, 343, Article d5928. 10.1136/bmj.d5928 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Krishnappa P., Fernandez-Pascual E., Carballido J., Martinez-Salamanca J. I. (2019). Sildenafil/Viagra in the treatment of premature ejaculation. International Journal of Impotence Research, 31(2), 65–70. 10.1038/s41443-018-0099-2 [DOI] [PubMed] [Google Scholar]
  12. Laumann E. O., Nicolosi A., Glasser D. B., Paik A., Gingell C., Moreira E., Wang T. (2005). Sexual problems among women and men aged 40-80 y: Prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. International Journal of Impotence Research, 17(1), 39–57. 10.1038/sj.ijir.3901250 [DOI] [PubMed] [Google Scholar]
  13. Leisegang K., Opuwari C. S., Moichela F., Finelli R. (2023). Traditional, complementary and alternative medicines in the treatment of ejaculatory disorders: A systematic review. Medicina (Kaunas), 59(9). 10.3390/medicina59091607 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mattos R. M., Marmo Lucon A., Srougi M. (2008). Tadalafil and fluoxetine in premature ejaculation: Prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis, 80(2), 162–165. 10.1159/000112607 [DOI] [PubMed] [Google Scholar]
  15. McMahon C. G., Jannini E. A., Serefoglu E. C., Hellstrom W. J. (2016). The pathophysiology of acquired premature ejaculation. Translational Andrology and Urology, 5(4), 434–449. 10.21037/tau.2016.07.06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mohamed Gharib T., Abdel-Al I., Elatreisy A., Kandeel W., El-Shaer W., Abdrabuh A. M., Mohamed Salih E., Sebaey A. (2022). Short-and long-term follow-up results of daily 5-mg tadalafil as a treatment for erectile dysfunction and premature ejaculation. Arab Journal of Urology, 20(1), 49–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ozcan L., Polat E. C., Onen E., Kocaaslan R., Otunctemur A., Cekmen M., Eraldemir C., Ozbek E. (2017). Effects of tadalafil 5 mg dosed once daily in men with premature ejaculation. Urologia Internationalis, 98(2), 210–214. 10.1159/000445839 [DOI] [PubMed] [Google Scholar]
  18. Patrick D. L., Althof S. E., Pryor J. L., Rosen R., Rowland D. L., Ho K. F., McNulty P., Rothman M., Jamieson C. (2005). Premature ejaculation: An observational study of men and their partners. Journal of Sexual Medicine, 2(3), 358–367. 10.1111/j.1743-6109.2005.20353.x [DOI] [PubMed] [Google Scholar]
  19. Pfaus J. G. (1999). Neurobiology of sexual behavior. Current Opinion in Neurobiology, 9(6), 751–758. 10.1016/s0959-4388(99)00034-3 [DOI] [PubMed] [Google Scholar]
  20. Raveendran A. V., Agarwal A. (2021). Premature ejaculation–current concepts in the management: A narrative review. International Journal of Reproductive BioMedicine, 19(1), 5–22. 10.18502/ijrm.v19i1.8176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Serefoglu E. C., McMahon C. G., Waldinger M. D., Althof S. E., Shindel A., Adaikan G., Becher E. F., Dean J., Giuliano F., Hellstrom W. J., Giraldi A., Glina S., Incrocci L., Jannini E., McCabe M., Parish S., Rowland D., Segraves R. T., Sharlip I., Torres L. O. (2014). An evidence-based unified definition of lifelong and acquired premature ejaculation: Report of the second international society for sexual medicine ad hoc committee for the definition of premature ejaculation. Sexual Medicine, 2(2), 41–59. 10.1002/sm2.27 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sun Y., Luo D., Yang L., Tang C., Yang T., Hu X., Shen H. (2015). Efficacy of phosphodiesterase-5 inhibitor in men with premature ejaculation: A new systematic review and meta-analysis. Urology, 86(5), 947–954. 10.1016/j.urology.2015.06.051 [DOI] [PubMed] [Google Scholar]
  23. Wang C. M., Wu B. R., Xiang P., Xiao J., Hu X. C. (2023). Management of male erectile dysfunction: From the past to the future. Frontiers in Endocrinology, 14, Article 1148834. 10.3389/fendo.2023.1148834 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Zhang X., Chi N., Sun M., Shan Z., Zhang Y., Cui Y. (2020). Phosphodiesterase-5 inhibitors for premature ejaculation: Systematic review and meta-analysis of placebo-controlled trials. American Journal of Men’s Health, 14(3), 1557988320916406. 10.1177/1557988320916406 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Men's Health are provided here courtesy of SAGE Publications

RESOURCES